Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T16:21:14.370Z.
Calculation as of: 2026-10-06T16:21:14.370Z.
Quote observation: 2026-10-06T16:20:48.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 533c4696450707580a389d0c8167e09da333cd728c1767827588ef029f48caf5
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
ArriVent BioPharma, Inc.
Market Cap
$705.14M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$711.01M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$716.46M
Operating Cash Flow Yield
46.05%
TTM Avg
23.51%
3Y Avg
20.54%
5Y Avg
18.34%
Market Cap
$717.52M
Operating Cash Flow Yield
N/A
TTM Avg
5.57%
3Y Avg
5.48%
5Y Avg
5.48%
Market Cap
$690.91M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$719.97M
Operating Cash Flow Yield
N/A
TTM Avg
4.26%
3Y Avg
2.63%
5Y Avg
1.85%
Market Cap
$680.69M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$735.04M
Operating Cash Flow Yield
N/A
TTM Avg
23.08%
3Y Avg
23.11%
5Y Avg
23.11%
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | $705.14M | N/A | N/A | N/A | N/A |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $711.01M | N/A | N/A | N/A | N/A |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $716.46M | 46.05% | 23.51% | 20.54% | 18.34% |
| Avalo Therapeutics, Inc. (AVTX)vs › | $717.52M | N/A | 5.57% | 5.48% | 5.48% |
| Anteris Technologies Global Corp. (AVR)vs › | $690.91M | N/A | N/A | N/A | N/A |
| Cytek Biosciences, Inc. (CTKB)vs › | $719.97M | N/A | 4.26% | 2.63% | 1.85% |
| Helus Pharma Inc. (HELP)vs › | $680.69M | N/A | N/A | N/A | N/A |
| Annexon, Inc. (ANNX)vs › | $679.13M | N/A | N/A | N/A | N/A |
| Achieve Life Sciences, Inc. (ACHV)vs › | $735.04M | N/A | 23.08% | 23.11% | 23.11% |
| Faeth Therapeutics, Inc. (FTH)vs › | $737.27M | N/A | N/A | N/A | N/A |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
